» Articles » PMID: 27999671

Plasma MicroRNA Biomarker Detection for Mild Cognitive Impairment Using Differential Correlation Analysis

Overview
Journal Biomark Res
Publisher Biomed Central
Date 2016 Dec 22
PMID 27999671
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mild cognitive impairment (MCI) is an intermediate state between normal aging and dementia including Alzheimer's disease. Early detection of dementia, and MCI, is a crucial issue in terms of secondary prevention. Blood biomarker detection is a possible way for early detection of MCI. Although disease biomarkers are detected by, in general, using single molecular analysis such as t-test, another possible approach is based on interaction between molecules.

Results: Differential correlation analysis, which detects difference on correlation of two variables in case/control study, was carried out to plasma microRNA (miRNA) expression profiles of 30 age- and race-matched controls and 23 Japanese MCI patients. The 20 pairs of miRNAs, which consist of 20 miRNAs, were selected as MCI markers. Two pairs of miRNAs (hsa-miR-191 and hsa-miR-101, and hsa-miR-103 and hsa-miR-222) out of 20 attained the highest area under the curve (AUC) value of 0.962 for MCI detection. Other two miRNA pairs that include hsa-miR-191 and hsa-miR-125b also attained high AUC value of ≥ 0.95. Pathway analysis was performed to the MCI markers for further understanding of biological implications. As a result, collapsed correlation on hsa-miR-191 and emerged correlation on hsa-miR-125b might have key role in MCI and dementia progression.

Conclusion: Differential correlation analysis, a bioinformatics tool to elucidate complicated and interdependent biological systems behind diseases, detects effective MCI markers that cannot be found by single molecule analysis such as t-test.

Citing Articles

MicroRNAs signatures as potential molecular markers in mild cognitive impairment: a meta-analysis.

Vargas-Rondon N, Gonzalez-Giraldo Y, Garcia Fonseca A, Gonzalez J, Aristizabal-Pachon A Front Aging Neurosci. 2025; 16:1524622.

PMID: 39881680 PMC: 11774935. DOI: 10.3389/fnagi.2024.1524622.


Biofluid biomarkers for Alzheimer's disease: past, present, and future.

An C, Cai H, Ren Z, Fu X, Quan S, Jia L Med Rev (2021). 2024; 4(6):467-491.

PMID: 39664082 PMC: 11629312. DOI: 10.1515/mr-2023-0071.


Genetic Associations of Plasminogen Activator Inhibitor-1-Related miRNA Variants with Coronary Artery Disease.

Ha Y, Sung J, Ryu C, Ko E, Park H, Park H Int J Mol Sci. 2024; 25(21).

PMID: 39519081 PMC: 11546797. DOI: 10.3390/ijms252111528.


Application of Multiomics Approach to Investigate the Therapeutic Potentials of Stem Cell-derived Extracellular Vesicle Subpopulations for Alzheimer's Disease.

Abyadeh M, Kaya A bioRxiv. 2024; .

PMID: 38798317 PMC: 11118424. DOI: 10.1101/2024.05.10.593647.


Identification of key regulatory molecules in the early development stage of Alzheimer's disease.

Huang B, Ou G, Zhang N J Cell Mol Med. 2024; 28(6):e18151.

PMID: 38429903 PMC: 10907834. DOI: 10.1111/jcmm.18151.


References
1.
Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

2.
Liang D, Han G, Feng X, Sun J, Duan Y, Lei H . Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One. 2012; 7(7):e40498. PMC: 3398025. DOI: 10.1371/journal.pone.0040498. View

3.
Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

4.
Hayes J, Peruzzi P, Lawler S . MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. DOI: 10.1016/j.molmed.2014.06.005. View

5.
Satoh J . Molecular network analysis of human microRNA targetome: from cancers to Alzheimer's disease. BioData Min. 2012; 5(1):17. PMC: 3492042. DOI: 10.1186/1756-0381-5-17. View